Catherine A Bonham1, Justin M Oldham2, Mardi Gomberg-Maitland3, Rekha Vij2. 1. Section of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, IL. Electronic address: catherine.bonham@uchospitals.edu. 2. Section of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, IL. 3. Section of Cardiology, University of Chicago, Chicago, IL.
Abstract
BACKGROUND: It is unclear whether recent advances in pulmonary arterial hypertension therapy can be safely applied to sarcoidosis-associated pulmonary hypertension (SAPH). Evidence for prostacyclin (PG) therapy in SAPH is limited. METHODS: We conducted a single-center, retrospective review of 46 patients with sarcoidosis, 26 of whom had SAPH. Thirteen received PG as monotherapy or in combination with oral vasodilators. RESULTS: Follow-up right-sided heart catheterization at a mean of 12.7 months revealed improved cardiac output, cardiac index, and pulmonary vascular resistance. Functional class and N-terminal pro-brain natriuretic peptide levels also improved in patients treated with PG. No significant change in oxygen requirement was seen with vasodilator therapy initiation. At 2 years, 15 patients with SAPH survived, including eight on PG, and at 5 years, seven survived, including five on PG. Survival was significantly reduced in patients with SAPH compared with patients who had sarcoidosis without pulmonary hypertension. Multivariate analysis demonstrated that the use of PG therapy in SAPH is not associated with increased mortality. CONCLUSIONS: Many patients with severe SAPH showed significant hemodynamic and clinical improvement on long-term IV or subcutaneous PG therapy and had survival outcomes similar to patients with moderate SAPH on oral vasodilator therapy.
BACKGROUND: It is unclear whether recent advances in pulmonary arterial hypertension therapy can be safely applied to sarcoidosis-associated pulmonary hypertension (SAPH). Evidence for prostacyclin (PG) therapy in SAPH is limited. METHODS: We conducted a single-center, retrospective review of 46 patients with sarcoidosis, 26 of whom had SAPH. Thirteen received PG as monotherapy or in combination with oral vasodilators. RESULTS: Follow-up right-sided heart catheterization at a mean of 12.7 months revealed improved cardiac output, cardiac index, and pulmonary vascular resistance. Functional class and N-terminal pro-brain natriuretic peptide levels also improved in patients treated with PG. No significant change in oxygen requirement was seen with vasodilator therapy initiation. At 2 years, 15 patients with SAPH survived, including eight on PG, and at 5 years, seven survived, including five on PG. Survival was significantly reduced in patients with SAPH compared with patients who had sarcoidosis without pulmonary hypertension. Multivariate analysis demonstrated that the use of PG therapy in SAPH is not associated with increased mortality. CONCLUSIONS: Many patients with severe SAPH showed significant hemodynamic and clinical improvement on long-term IV or subcutaneous PG therapy and had survival outcomes similar to patients with moderate SAPH on oral vasodilator therapy.
Authors: Kimberly A Fisher; David M Serlin; Kevin C Wilson; Robert E Walter; Jeffrey S Berman; Harrison W Farber Journal: Chest Date: 2006-11 Impact factor: 9.410
Authors: Nils Milman; Christopher M Burton; Martin Iversen; Regitze Videbaek; Claus V Jensen; Jørn Carlsen Journal: J Heart Lung Transplant Date: 2008-03 Impact factor: 10.247
Authors: Steven D Nathan; Joan A Barbera; Sean P Gaine; Sergio Harari; Fernando J Martinez; Horst Olschewski; Karen M Olsson; Andrew J Peacock; Joanna Pepke-Zaba; Steeve Provencher; Norbert Weissmann; Werner Seeger Journal: Eur Respir J Date: 2019-01-24 Impact factor: 16.671
Authors: Robert P Baughman; Oksana A Shlobin; Rohit Gupta; Peter J Engel; Jeffrey I Stewart; Elyse E Lower; Franck F Rahaghi; Joyce Zeigler; Steven D Nathan Journal: Chest Date: 2021-08-04 Impact factor: 9.410
Authors: Pratik S Velangi; Ko-Hsuan Amy Chen; Felipe Kazmirczak; Osama Okasha; Lisa von Wald; Henri Roukoz; Afshin Farzaneh-Far; Jeremy Markowitz; Prabhjot S Nijjar; Maneesh Bhargava; David Perlman; Mehmet Akçakaya; Chetan Shenoy Journal: JACC Cardiovasc Imaging Date: 2020-01-15